Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors (original) (raw)

• Centers for Disease Control and Prevention. National Diabetes Statistical Report. Centers for Disease Control and Prevention https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf (2020).
• Koye, D. N., Magliano, D. J., Nelson, R. G. & Pavkov, M. E. The global epidemiology of diabetes and kidney disease. Adv. Chronic Kidney Dis. 25, 121–132 (2018).
  Article PubMed Google Scholar
• Gregg, E. W. et al. Changes in diabetes-related complications in the United States, 1990–2010. N. Engl. J. Med. 370, 1514–1523 (2014). Unlike the prevalence of other diabetic microvascular and macrovascular complications, which have decreased over the past 10–20 years, the prevalence of DKD has remained unchanged.
  Article CAS PubMed Google Scholar
• Lytvyn, Y., Bjornstad, P., van Raalte, D. H., Heerspink, H. L. & Cherney, D. Z. I. The new biology of diabetic kidney disease-mechanisms and therapeutic implications. Endocr. Rev. 41, 202–231 (2020). An excellent review of therapies for DKD currently in use or in clinical development.
  Article Google Scholar
• Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).
  Article CAS PubMed Google Scholar
• Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).
  Article CAS PubMed Google Scholar
• Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347–357 (2019).
  Article CAS PubMed Google Scholar
• Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019). A large prospective study that demonstrated the efficacy of the SGLT2 inhibitor canagliflozin in slowing the progression of kidney disease in patients with established DKD and resulted in approval of the drug by the FDA.
  Article CAS PubMed Google Scholar
• Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436–1446 (2020).
  Article CAS PubMed Google Scholar
• Umanath, K. & Lewis, J. B. Update on diabetic nephropathy: core curriculum 2018. Am. J. Kidney Dis. 71, 884–895 (2018).
  Article PubMed Google Scholar
• Tonneijck, L. et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J. Am. Soc. Nephrol. 28, 1023–1039 (2017). Excellent, up-to-date review about the origin, significance and treatment of hyperfiltration in diabetic nephropathy.
  Article CAS PubMed PubMed Central Google Scholar
• Markus, M. R. P. et al. Prediabetes is associated with microalbuminuria, reduced kidney function and chronic kidney disease in the general population: The KORA (Cooperative Health Research in the Augsburg Region) F4-Study. Nutr. Metab. Cardiovasc. Dis. 28, 234–242 (2018).
  Article CAS PubMed Google Scholar
• Diabetes, C. et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977–986 (1993). Landmark study demonstrating the importance of tight glycaemic control in the prevention of microvascular complications in patients with type 1 diabetes.
  Article Google Scholar
• American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2018. Diabetes Care 41, S55–S64 (2018).
  Article Google Scholar
• Diabetes, C. et al. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N. Engl. J. Med. 342, 381–389 (2000).
  Article Google Scholar
• Nathan, D. M. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353, 2643–2653 (2005).
  Article PubMed Google Scholar
• Stratton, I. M. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321, 405–412 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Group, A. C. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560–2572 (2008).
  Article Google Scholar
• Ismail-Beigi, F. et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376, 419–430 (2010).
  Article PubMed PubMed Central Google Scholar
• Brocco, E. et al. Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy. J. Nephrol. 14, 461–471 (2001).
  CAS PubMed Google Scholar
• Zoungas, S. et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 32, 2068–2074 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Tamborlane, W. V. et al. Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy. Diabetes Care 5, 58–64 (1982). Although the number of patients with diabetes was small, this study demonstrated that intensive glycaemic control with insulin in patients with type 1 diabetes cannot slow the progression of DKD once macroalbuminuria is established.
  PubMed Google Scholar
• Ciavarella, A. et al. Effect of long-term near-normoglycemia on the progression of diabetic nephropathy. Diabete Metab. 11, 3–8 (1985).
  CAS PubMed Google Scholar
• Caramori, M. L., Fioretto, P. & Mauer, M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 52, 1036–1040 (2003).
  Article CAS PubMed Google Scholar
• Merovci, A. et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest. 124, 509–514 (2014). To our knowledge the first study to examine the mechanisms by which SGLT2 inhibitors improve glycaemic control in patients with diabetes.
  Article CAS PubMed PubMed Central Google Scholar
• DeFronzo, R. A., Norton, L. & Abdul-Ghani, M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 13, 11–26 (2017). Comprehensive review of the pleiotrophic effects of SGLT2 inhibitors in humans.
  Article CAS PubMed Google Scholar
• DeFronzo, R. A. et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36, 3169–3176 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Merovci, A. et al. Dapagliflozin lowers plasma glucose concentration and improves beta-cell function. J. Clin. Endocrinol. Metab. 100, 1927–1932 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Al Jobori, H. et al. Empagliflozin treatment is associated with improved beta-cell function in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 103, 1402–1407 (2018).
  Article PubMed PubMed Central Google Scholar
• Yki-Jarvinen, H Glucose toxicity. in International Textbook of Diabetes Mellitus. 4th edn. 413-425 (Wiley, 2015).
• Parving, H. H., Andersen, A. R., Smidt, U. M. & Svendsen, P. A. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1, 1175–1179 (1983). One of the earliest publications demonstrating the powerful effect of antihypertensive therapy in slowing the rate of GFR decline in patients with established DKD.
  Article CAS PubMed Google Scholar
• Xie, X. et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 387, 435–443 (2016).
  Article PubMed Google Scholar
• Patney, V., Whaley-Connell, A. & Bakris, G. Hypertension management in DKD. Diabetes Spectr. 28, 175–180 (2015).
  Article PubMed PubMed Central Google Scholar
• Group, A. S. et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575–1585 (2010).
  Article CAS Google Scholar
• Group, S. R. et al. A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 373, 2103–2116 (2015).
  Article CAS Google Scholar
• Warren, A. M., Knudsen, S. T. & Cooper, M. E. Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies. Expert Opin. Ther. Targets 23, 579–591 (2019).
  Article PubMed Google Scholar
• Ruggenenti, P., Cravedi, P. & Remuzzi, G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat. Rev. Nephrol. 6, 319–330 (2010). Excellent review of the renin–angiotensin–aldosterone system in the pathogenesis and treatment of DKD.
  Article CAS PubMed Google Scholar
• van den Meiracker, A. H. et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J. Hypertens. 10, 803–812 (1992).
  PubMed Google Scholar
• Ingelfinger, J. R. Aliskiren and dual therapy in type 2 diabetes mellitus. N. Engl. J. Med. 358, 2503–2505 (2008).
  Article CAS PubMed Google Scholar
• Bolignano, D., Palmer, S. C., Navaneethan, S. D. & Strippoli, G. F. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD007004.pub3 (2014).
  Article PubMed Google Scholar
• Morales, E. et al. Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases. Nephrol. Dial. Transpl. 28, 405–412 (2013).
  Article CAS Google Scholar
• Cherney, D. Z. et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129, 587–597 (2014). Well-designed study demonstrating that inhibition of the SGLT2 cotransporter reverses hyperfiltration in patients with type 1 diabetes.
  Article CAS PubMed Google Scholar
• Scheen, A. J. & Delanaye, P. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Metab. 43, 99–109 (2017).
  Article CAS PubMed Google Scholar
• Brenner, B. M. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int. 23, 647–655 (1983). The role of altered tubuloglomerular feedback, increased intraglomerular pressure, and hyperfiltration in the development and progression of chronic kidney disease is reviewed by the original proponent of the haemodynamic theory of glomerular injury.
  Article CAS PubMed Google Scholar
• Thomson, S. C. & Blantz, R. C. Glomerulotubular balance, tubuloglomerular feedback, and salt homeostasis. J. Am. Soc. Nephrol. 19, 2272–2275 (2008).
  Article PubMed Google Scholar
• Vallon, V. et al. Adenosine A(1) receptors determine glomerular hyperfiltration and the salt paradox in early streptozotocin diabetes mellitus. Nephron Physiol. 111, p30–p38 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Sallstrom, J. et al. Diabetes-induced hyperfiltration in adenosine A(1)-receptor deficient mice lacking the tubuloglomerular feedback mechanism. Acta Physiol. 190, 253–259 (2007).
  Article CAS Google Scholar
• Gallo, L. A., Wright, E. M. & Vallon, V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc. Dis. Res. 12, 78–89 (2015).
  Article CAS PubMed Google Scholar
• Bank, N. & Aynedjian, H. S. Progressive increases in luminal glucose stimulate proximal sodium absorption in normal and diabetic rats. J. Clin. Invest. 86, 309–316 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Vallon, V. & Thomson, S. C. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu. Rev. Physiol. 74, 351–375 (2012). Review of evidence supporting enhanced glucose-coupled sodium reabsorption by the proximal tubule in the development of increased intraglomerular pressure, hyperfiltration and diabetic glomerular injury.
  Article CAS PubMed Google Scholar
• Vallon, V., Richter, K., Blantz, R. C., Thomson, S. & Osswald, H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J. Am. Soc. Nephrol. 10, 2569–2576 (1999).
  CAS PubMed Google Scholar
• Bjornstad, P. et al. Rapid GFR decline is associated with renal hyperfiltration and impaired GFR in adults with Type 1 diabetes. Nephrol. Dial. Transpl. 30, 1706–1711 (2015). Prospective clinical study demonstrating that hyperfiltration predicts the decline in GFR in patients with type 1 diabetes.
  Article Google Scholar
• Magee, G. M. et al. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 52, 691–697 (2009).
  Article CAS PubMed Google Scholar
• Ruggenenti, P. et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 35, 2061–2068 (2012). Prospective clinical study demonstrating that hyperfiltration predicts the decline in GFR in patients with type 2 diabetes.
  Article CAS PubMed PubMed Central Google Scholar
• Nelson, R. G. et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N. Engl. J. Med. 335, 1636–1642 (1996).
  Article CAS PubMed Google Scholar
• Jerums, G., Premaratne, E., Panagiotopoulos, S. & MacIsaac, R. J. The clinical significance of hyperfiltration in diabetes. Diabetologia 53, 2093–2104 (2010).
  Article CAS PubMed Google Scholar
• Vestri, S. et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J. Membr. Biol. 182, 105–112 (2001).
  Article CAS PubMed Google Scholar
• Tabatabai, N. M., Sharma, M., Blumenthal, S. S. & Petering, D. H. Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats. Diabetes Res. Clin. Pract. 83, e27–e30 (2009).
  Article CAS PubMed Google Scholar
• Albertoni Borghese, M. F. et al. Expression and activity of SGLT2 in diabetes induced by streptozotocin: relationship with the lipid environment. Nephron Physiol. 112, p45–p52 (2009).
  Article CAS PubMed Google Scholar
• Norton, L. et al. Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects. Diabetes Obes. Metab. 19, 1322–1326 (2017). Renal biopsy study demonstrating that the gene transcript for SGLT1 is increased in patients with diabetes, whereas the gene transcript for SGLT2 is normal to decreased.
  Article CAS PubMed Google Scholar
• Solini, A. et al. Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes. Diabetes Obes. Metab. 19, 1289–1294 (2017).
  Article CAS PubMed Google Scholar
• Vallon, V. et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am. J. Physiol. Ren. Physiol. 304, F156–F167 (2013). Classic study documenting that knockout of the SGLT2 transporter in the proximal tubule ameliorates hyperfiltration in diabetic mice.
  Article CAS Google Scholar
• Thomson, S. C. et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302, R75–R83 (2012).
  Article CAS PubMed Google Scholar
• Terami, N. et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS ONE 9, e100777 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Kidokoro, K. et al. Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging. Circulation 140, 303–315 (2019).
  Article CAS PubMed Google Scholar
• van Bommel, E. J. M. et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int. 97, 202–212 (2020). Provocative clinical study demonstrating that the SGLT2 inhibitor dapagliflozin reduces GFR intraglomerular pressure by causing vasodilation of the efferent arteriole in patients with type 2 diabetes, indicating that the renal haemodynamic effects in these individuals are distinct from those in patients with type 1 diabetes.
  Article PubMed CAS Google Scholar
• Fioretto, P., Zambon, A., Rossato, M., Busetto, L. & Vettor, R. SGLT2 inhibitors and the diabetic kidney. Diabetes Care 39, S165–S171 (2016).
  Article CAS PubMed Google Scholar
• Denic, A. et al. Single-nephron glomerular filtration rate in healthy adults. N. Engl. J. Med. 376, 2349–2357 (2017).
  Article PubMed PubMed Central Google Scholar
• van der Sande, N. G. et al. High ratios of kidney function to kidney size are related to mortality and kidney function decline in high-risk patients. Eur. J. Prev. Cardiol. 24, 926–933 (2017).
  Article PubMed Google Scholar
• Altay, S. et al. Renal “hyperfiltrators” are at elevated risk of death and chronic diseases. BMC Nephrol. 15, 160 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Rigalleau, V. et al. Large kidneys predict poor renal outcome in subjects with diabetes and chronic kidney disease. BMC Nephrol. 11, 3 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Hostetter, T. H. Hypertrophy and hyperfunction of the diabetic kidney. J. Clin. Invest. 107, 161–162 (2001). Insightful discussion about whether glomerular hypertrophy begets hyperfiltration or hyperfiltration begets glomerular hypertrophy in the development of DKD.
  Article CAS PubMed PubMed Central Google Scholar
• Thomas, M. C., Burns, W. C. & Cooper, M. E. Tubular changes in early diabetic nephropathy. Adv. Chronic Kidney Dis. 12, 177–186 (2005).
  Article CAS PubMed Google Scholar
• Tuttle, K. R. et al. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N. Engl. J. Med. 324, 1626–1632 (1991). Clinical study that conclusively demonstrates that strict glycaemic control with insulin reverses renal hypertrophy and the exaggerated rise in GFR in response to amino acids.
  Article CAS PubMed Google Scholar
• Wolf, G. & Neilson, E. G. Angiotensin II as a renal growth factor. J. Am. Soc. Nephrol. 3, 1531–1540 (1993).
  CAS PubMed Google Scholar
• Huang, H. C. & Preisig, P. A. G1 kinases and transforming growth factor-beta signaling are associated with a growth pattern switch in diabetes-induced renal growth. Kidney Int. 58, 162–172 (2000).
  Article CAS PubMed Google Scholar
• Deng, A. et al. Increased expression of ornithine decarboxylase in distal tubules of early diabetic rat kidneys: are polyamines paracrine hypertrophic factors? Diabetes 52, 1235–1239 (2003).
  Article CAS PubMed Google Scholar
• Thomson, S. C. et al. Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J. Clin. Invest. 107, 217–224 (2001). Landmark study demonstrating that tubular hypertrophy precedes glomerular hypertrophy and that inhibition of tubular hypertrophy with an inhibitor of ornithine decarboxylase prevents subsequent glomerular hypertrophy, hyperfiltration and DKD.
  Article CAS PubMed PubMed Central Google Scholar
• Chiarelli, F., Gaspari, S. & Marcovecchio, M. L. Role of growth factors in diabetic kidney disease. Horm. Metab. Res. 41, 585–593 (2009).
  Article CAS PubMed Google Scholar
• Qi, W., Chen, X., Poronnik, P. & Pollock, C. A. Transforming growth factor-beta/connective tissue growth factor axis in the kidney. Int. J. Biochem. Cell Biol. 40, 9–13 (2008).
  Article CAS PubMed Google Scholar
• Iwano, M. et al. Quantification of glomerular TGF-beta 1 mRNA in patients with diabetes mellitus. Kidney Int. 49, 1120–1126 (1996).
  Article CAS PubMed Google Scholar
• Yamamoto, T., Nakamura, T., Noble, N. A., Ruoslahti, E. & Border, W. A. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc. Natl Acad. Sci. USA 90, 1814–1818 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• McGowan, T. A., Zhu, Y. & Sharma, K. Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy. Curr. Diab Rep. 4, 447–454 (2004).
  Article PubMed Google Scholar
• Voelker, J. et al. Anti-TGF-beta1 antibody therapy in patients with diabetic nephropathy. J. Am. Soc. Nephrol. 28, 953–962 (2017). Large prospective clinical trial in which an anti-TGFβ1 antibody failed to slow the progression of DKD.
  Article CAS PubMed Google Scholar
• van Nieuwenhoven, F. A., Jensen, L. J., Flyvbjerg, A. & Goldschmeding, R. Imbalance of growth factor signalling in diabetic kidney disease: is connective tissue growth factor (CTGF, CCN2) the perfect intervention point? Nephrol. Dial. Transpl. 20, 6–10 (2005).
  Article Google Scholar
• Riser, B. L. et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J. Am. Soc. Nephrol. 11, 25–38 (2000).
  CAS PubMed Google Scholar
• Wahab, N. A., Weston, B. S. & Mason, R. M. Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor TrkA. J. Am. Soc. Nephrol. 16, 340–351 (2005).
  Article CAS PubMed Google Scholar
• Guha, M., Xu, Z. G., Tung, D., Lanting, L. & Natarajan, R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J. 21, 3355–3368 (2007).
  Article CAS PubMed Google Scholar
• Adler, S. G. et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin. J. Am. Soc. Nephrol. 5, 1420–1428 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Vallon, V. & Thomson, S. C. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat. Rev. Nephrol. 16, 317–336 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Fine, L. G., Orphanides, C. & Norman, J. T. Progressive renal disease: the chronic hypoxia hypothesis. Kidney Int. Suppl. 65, S74–S78 (1998). Early review proposing renal hypoxia as a causative factor in the development of DKD.
  CAS PubMed Google Scholar
• Mimura, I. & Nangaku, M. The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat. Rev. Nephrol. 6, 667–678 (2010).
  Article CAS PubMed Google Scholar
• Korner, A., Eklof, A. C., Celsi, G. & Aperia, A. Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes 43, 629–633 (1994).
  Article CAS PubMed Google Scholar
• Layton, A. T., Vallon, V. & Edwards, A. Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron. Am. J. Physiol. Ren. Physiol. 310, F1269–F1283 (2016). Review of oxygen consumption by nephron segments and the predicted effect of SGLT2 inhibition on sodium transport and oxygen utlization in these segments.
  Article CAS Google Scholar
• Soltoff, S. P. ATP and the regulation of renal cell function. Annu. Rev. Physiol. 48, 9–31 (1986).
  Article CAS PubMed Google Scholar
• Layton, A. T., Laghmani, K., Vallon, V. & Edwards, A. Solute transport and oxygen consumption along the nephrons: effects of Na+ transport inhibitors. Am. J. Physiol. Ren. Physiol. 311, F1217–F1229 (2016).
  Article CAS Google Scholar
• Franzen, S., Pihl, L., Khan, N., Gustafsson, H. & Palm, F. Pronounced kidney hypoxia precedes albuminuria in type 1 diabetic mice. Am. J. Physiol. Ren. Physiol. 310, F807–F809 (2016).
  Article CAS Google Scholar
• Blantz, R. C., Deng, A., Miracle, C. M. & Thomson, S. C. Regulation of kidney function and metabolism: a question of supply and demand. Trans. Am. Clin. Climatol. Assoc. 118, 23–43 (2007).
  PubMed PubMed Central Google Scholar
• Inoue, T. et al. Noninvasive evaluation of kidney hypoxia and fibrosis using magnetic resonance imaging. J. Am. Soc. Nephrol. 22, 1429–1434 (2011).
  Article PubMed PubMed Central Google Scholar
• Basile, D. P., Donohoe, D., Roethe, K. & Osborn, J. L. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am. J. Physiol. Ren. Physiol. 281, F887–F899 (2001).
  Article CAS Google Scholar
• Kong, T., Eltzschig, H. K., Karhausen, J., Colgan, S. P. & Shelley, C. S. Leukocyte adhesion during hypoxia is mediated by HIF-1-dependent induction of beta2 integrin gene expression. Proc. Natl Acad. Sci. USA 101, 10440–10445 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Postlethwaite, A. E., Shigemitsu, H. & Kanangat, S. Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr. Opin. Rheumatol. 16, 733–738 (2004).
  Article PubMed Google Scholar
• Deng, A. et al. Renal protection in chronic kidney disease: hypoxia-inducible factor activation vs. angiotensin II blockade. Am. J. Physiol. Renal Physiol. 299, F1365–F1373 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Rosenberger, C. et al. Adaptation to hypoxia in the diabetic rat kidney. Kidney Int. 73, 34–42 (2008).
  Article CAS PubMed Google Scholar
• Eckardt, K. U., Bernhardt, W., Willam, C. & Wiesener, M. Hypoxia-inducible transcription factors and their role in renal disease. Semin. Nephrol. 27, 363–372 (2007).
  Article CAS PubMed Google Scholar
• Persson, P. & Palm, F. Hypoxia-inducible factor activation in diabetic kidney disease. Curr. Opin. Nephrol. Hypertens. 26, 345–350 (2017). Supporting evidence for the role of HIF and renal hypoxia in the development of DKD.
  Article CAS PubMed Google Scholar
• Garcia-Pastor, C., Benito-Martinez, S., Moreno-Manzano, V., Fernandez-Martinez, A. B. & Lucio-Cazana, F. J. Mechanism and consequences of The impaired Hif-1alpha response to hypoxia in human proximal tubular HK-2 cells exposed to high glucose. Sci. Rep. 9, 15868 (2019).
  Article PubMed PubMed Central CAS Google Scholar
• O’Neill, J. et al. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am. J. Physiol. Renal Physiol. 309, F227–F234 (2015).
  Article PubMed CAS Google Scholar
• Ghanim, H. et al. Dapagliflozin suppresses hepcidin and increases erythropoiesis. J. Clin. Endocrinol. Metab. 105, dgaa057 (2020).
  Article PubMed Google Scholar
• Mudaliar, S., Alloju, S. & Henry, R. R. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? A unifying hypothesis. Diabetes Care 39, 1115–1122 (2016). Hypothesis and supporting evidence for energy depravation in the aetiology of diabetic renal disease.
  Article CAS PubMed Google Scholar
• Little, J. R. & Spitzer, J. J. Uptake of ketone bodies by dog kidney in vivo. Am. J. Physiol. 221, 679–683 (1971).
  Article CAS PubMed Google Scholar
• Sato, K. et al. Insulin, ketone bodies, and mitochondrial energy transduction. FASEB J. 9, 651–658 (1995).
  Article CAS PubMed Google Scholar
• Ferrannini, E., Mark, M. & Mayoux, E. CV Protection in the EMPA-REG OUTCOME Trial: a “thrifty substrate” hypothesis. Diabetes Care 39, 1108–1114 (2016). Novel hypothesis that ketones function as a “super fuel” for the heart and explain, in part, the beneficial cardiovascular effects of the SGLT2 inhibitor class of drugs.
  Article PubMed Google Scholar
• Scandling, J. D. & Myers, B. D. Glomerular size-selectivity and microalbuminuria in early diabetic glomerular disease. Kidney Int. 41, 840–846 (1992).
  Article CAS PubMed Google Scholar
• Nakamura, Y. & Myers, B. D. Charge selectivity of proteinuria in diabetic glomerulopathy. Diabetes 37, 1202–1211 (1988).
  Article CAS PubMed Google Scholar
• Steffes, M. W., Schmidt, D., McCrery, R., Basgen, J. M. & International Diabetic Nephropathy Study Group. Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int. 59, 2104–2113 (2001).
  Article CAS PubMed Google Scholar
• Pagtalunan, M. E. et al. Podocyte loss and progressive glomerular injury in type II diabetes. J. Clin. Invest. 99, 342–348 (1997). Renal biopsy study in Pima Indians with type 2 diabetes with varying degrees of kidney disease demonstrating that with advancing severity of glomerulosclerosis there is a progressive loss of podocytes.
  Article CAS PubMed PubMed Central Google Scholar
• Tamsma, J. T. et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 37, 313–320 (1994).
  Article CAS PubMed Google Scholar
• de Vries, A. P. et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2, 417–426 (2014). Review of evidence supporting lipid deposition in the kidney as a causative factor in the development of obesity-related glomerulosclerosis and hyperfiltration, as a distinct entity from diabetic nephropathy.
  Article PubMed CAS Google Scholar
• Nishi, H. & Nangaku, M. Podocyte lipotoxicity in diabetic kidney disease. Kidney Int. 96, 809–812 (2019).
  Article PubMed Google Scholar
• Sieber, J. et al. Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids. Am. J. Physiol. Ren. Physiol. 299, F821–F829 (2010).
  Article CAS Google Scholar
• Wang, Z. et al. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 54, 2328–2335 (2005).
  Article CAS PubMed Google Scholar
• Hale, L. J. & Coward, R. J. The insulin receptor and the kidney. Curr. Opin. Nephrol. Hypertens. 22, 100–106 (2013).
  Article CAS PubMed Google Scholar
• Welsh, G. I. et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab. 12, 329–340 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Russo, L. M. et al. Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J. Am. Soc. Nephrol. 20, 489–494 (2009).
  Article PubMed PubMed Central Google Scholar
• Abbate, M., Zoja, C. & Remuzzi, G. How does proteinuria cause progressive renal damage? J. Am. Soc. Nephrol. 17, 2974–2984 (2006).
  Article CAS PubMed Google Scholar
• Burton, C. & Harris, K. P. The role of proteinuria in the progression of chronic renal failure. Am. J. Kidney Dis. 27, 765–775 (1996).
  Article CAS PubMed Google Scholar
• Dixon, R. & Brunskill, N. J. Activation of mitogenic pathways by albumin in kidney proximal tubule epithelial cells: implications for the pathophysiology of proteinuric states. J. Am. Soc. Nephrol. 10, 1487–1497 (1999).
  CAS PubMed Google Scholar
• Heerspink, H. J. L. et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 7, 128–139 (2019). Metaanalysis proposing albuminuria as a surrogate end point for progression of renal disease and providing evidence for a toxic effect of albumin on the kidney.
  Article CAS PubMed Google Scholar
• Cassis, P. et al. SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. JCI Insight 3, e98720 (2018).
  Article PubMed Central Google Scholar
• Korbut, A. I. et al. SGLT2 inhibitor empagliflozin and DPP4 inhibitor linagliptin reactivate glomerular autophagy in db/db Mice, a model of type 2 diabetes. Int. J. Mol. Sci. 21, 2987 (2020).
  Article CAS PubMed Central Google Scholar
• Herman-Edelstein, M., Scherzer, P., Tobar, A., Levi, M. & Gafter, U. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J. Lipid Res. 55, 561–572 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, H. M. et al. Podocyte lesions in patients with obesity-related glomerulopathy. Am. J. Kidney Dis. 48, 772–779 (2006).
  Article PubMed Google Scholar
• Sharma, S. G. et al. The modern spectrum of renal biopsy findings in patients with diabetes. Clin. J. Am. Soc. Nephrol. 8, 1718–1724 (2013).
  Article PubMed PubMed Central Google Scholar
• Belfort, R. et al. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes 54, 1640–1648 (2005).
  Article CAS PubMed Google Scholar
• Kashyap, S. et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 52, 2461–2474 (2003).
  Article CAS PubMed Google Scholar
• Cooper, M. E. & Jandeleit-Dahm, K. A. Lipids and diabetic renal disease. Curr. Diab Rep. 5, 445–448 (2005). Review of evidence supporting glomerular and tubular lipid deposition in the development of diabetic kidney injury.
  Article CAS PubMed Google Scholar
• Shevalye, H. et al. Prediabetic nephropathy as an early consequence of the high-calorie/high-fat diet: relation to oxidative stress. Endocrinology 153, 1152–1161 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Sun, Y. B. et al. Smad3 deficiency protects mice from obesity-induced podocyte injury that precedes insulin resistance. Kidney Int. 88, 286–298 (2015).
  Article CAS PubMed Google Scholar
• Grove, K. J. et al. Diabetic nephropathy induces alterations in the glomerular and tubule lipid profiles. J. Lipid Res. 55, 1375–1385 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Jiang, T. et al. Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J. Biol. Chem. 280, 32317–32325 (2005).
  Article CAS PubMed Google Scholar
• Zhao, X. et al. Kidney injury molecule-1 is upregulated in renal lipotoxicity and mediates palmitate-induced tubular cell injury and inflammatory response. Int J. Mol. Sci. 20, 3406 (2019).
  Article PubMed Central CAS Google Scholar
• Kim, M. Y. et al. Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1alpha axis in db/db mice. Diabetologia 56, 204–217 (2013).
  Article CAS PubMed Google Scholar
• Rosca, M. G. et al. Oxidation of fatty acids is the source of increased mitochondrial reactive oxygen species production in kidney cortical tubules in early diabetes. Diabetes 61, 2074–2083 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Ohse, T. et al. Albumin induces endoplasmic reticulum stress and apoptosis in renal proximal tubular cells. Kidney Int. 70, 1447–1455 (2006).
  Article CAS PubMed Google Scholar
• Falkevall, A. et al. Reducing VEGF-B signaling ameliorates renal lipotoxicity and protects against diabetic kidney disease. Cell Metab. 25, 713–726 (2017).
  Article CAS PubMed Google Scholar
• Ferrannini, E. et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest. 124, 499–508 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Nikolic-Paterson, D. J. & Atkins, R. C. The role of macrophages in glomerulonephritis. Nephrol. Dial. Transpl. 16, 3–7 (2001).
  Article CAS Google Scholar
• Perez-Morales, R. E. et al. Inflammation in diabetic kidney disease. Nephron 143, 12–16 (2019). Review of inflammatory pathways that are activated in animal models of diabetes and their potential role in the development of diabetic nephropathy.
  Article CAS PubMed Google Scholar
• Alicic, R. Z., Johnson, E. J. & Tuttle, K. R. Inflammatory mechanisms as new biomarkers and therapeutic targets for diabetic kidney disease. Adv. Chronic Kidney Dis. 25, 181–191 (2018).
  Article PubMed Google Scholar
• Ruster, C. & Wolf, G. The role of chemokines and chemokine receptors in diabetic nephropathy. Front. Biosci. 13, 944–955 (2008).
  Article CAS PubMed Google Scholar
• Dekkers, C. C. J. et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes. Metab. 20, 1988–1993 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Okada, S. et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 52, 2586–2593 (2003).
  Article CAS PubMed Google Scholar
• Nguyen, D. et al. Macrophage accumulation in human progressive diabetic nephropathy. Nephrology 11, 226–231 (2006).
  Article PubMed Google Scholar
• You, H., Gao, T., Cooper, T. K., Brian Reeves, W. & Awad, A. S. Macrophages directly mediate diabetic renal injury. Am. J. Physiol. Renal Physiol. 305, F1719–F1727 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Awad, A. S. et al. Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. Am. J. Physiol. Renal Physiol. 301, F1358–F1366 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• de Zeeuw, D. et al. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol. 3, 687–696 (2015).
  Article PubMed CAS Google Scholar
• Sriwijitkamol, A. et al. Reduced skeletal muscle inhibitor of kappaB beta content is associated with insulin resistance in subjects with type 2 diabetes: reversal by exercise training. Diabetes 55, 760–767 (2006).
  Article CAS PubMed Google Scholar
• Barnes, P. J. & Karin, M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336, 1066–1071 (1997).
  Article CAS PubMed Google Scholar
• de Zeeuw, D. et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 369, 2492–2503 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Marrero, M. B., Banes-Berceli, A. K., Stern, D. M. & Eaton, D. C. Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 290, F762–F768 (2006).
  Article CAS PubMed Google Scholar
• Berthier, C. C. et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 58, 469–477 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Choudhury, G. G., Ghosh-Choudhury, N. & Abboud, H. E. Association and direct activation of signal transducer and activator of transcription1alpha by platelet-derived growth factor receptor. J. Clin. Invest. 101, 2751–2760 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Woroniecka, K. I. et al. Transcriptome analysis of human diabetic kidney disease. Diabetes 60, 2354–2369 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Brosius, F. C. III & He, J. C. JAK inhibition and progressive kidney disease. Curr. Opin. Nephrol. Hypertens. 24, 88–95 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, H. et al. Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice. Kidney Int. 92, 909–921 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Tuttle, K. R. et al. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. Nephrol. Dial. Transpl. 33, 1950–1959 (2018).
  Article CAS Google Scholar
• Ortiz-Munoz, G. et al. Suppressors of cytokine signaling abrogate diabetic nephropathy. J. Am. Soc. Nephrol. 21, 763–772 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Amiri, F. et al. Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int. 61, 1605–1616 (2002).
  Article CAS PubMed Google Scholar
• Bonnet, F. & Scheen, A. J. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab. 44, 457–464 (2018).
  Article CAS PubMed Google Scholar
• Yaribeygi, H., Butler, A. E., Atkin, S. L., Katsiki, N. & Sahebkar, A. Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kindey disease: possible molecualr pathways. J. Cell Physiol. 234, 223–230 (2019).
  Article CAS Google Scholar
• Jaikumkao, K. et al. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats. Diabetes Obes. Metab. 20, 2617–2626 (2018).
  Article CAS PubMed Google Scholar
• Kim, S. R. et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat. Commun. 11, 2127 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Heerspink, H. J. L. et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia 62, 1154–1166 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, T. M., Chang, N. C. & Lin, S. Z. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic. Biol. Med. 104, 298–310 (2017).
  Article CAS PubMed Google Scholar
• Kang, S. et al. Direct effects of empagliflozin on extracellular matrix remodeling in human cardiac fibroblasts: novel translational clues to EMPA-REG Outcome. Can. J. Cardiol. 33, S169 (2017).
  Article Google Scholar
• Goligorsky, M. S., Chen, J. & Brodsky, S. Workshop: endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension 37, 744–748 (2001).
  Article CAS PubMed Google Scholar
• Xia, Y., Dawson, V. L., Dawson, T. M., Snyder, S. H. & Zweier, J. L. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc. Natl Acad. Sci. USA 93, 6770–6774 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Brodsky, S. V., Gao, S., Li, H. & Goligorsky, M. S. Hyperglycemic switch from mitochondrial nitric oxide to superoxide production in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 283, H2130–H2139 (2002).
  Article CAS PubMed Google Scholar
• Wang, C. H. et al. A modest decrease in endothelial NOS in mice comparable to that associated with human NOS3 variants exacerbates diabetic nephropathy. Proc. Natl Acad. Sci. USA 108, 2070–2075 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Zhao, H. J. et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J. Am. Soc. Nephrol. 17, 2664–2669 (2006).
  Article CAS PubMed Google Scholar
• Morris, S. M. Jr. Gao, T., Cooper, T. K., Kepka-Lenhart, D. & Awad, A. S. Arginase-2 mediates diabetic renal injury. Diabetes 60, 3015–3022 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• You, H., Gao, T., Cooper, T. K., Morris, S. M. Jr. & Awad, A. S. Arginase inhibition: a new treatment for preventing progression of established diabetic nephropathy. Am. J. Physiol. Ren. Physiol. 309, F447–F455 (2015). Evidence supporting the role of arginase inhibition in preventing kidney disease in a murine model of diabetes.
  Article CAS Google Scholar
• You, H., Gao, T., Cooper, T. K., Morris, S. M. Jr. & Awad, A. S. Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism. Kidney Int. 84, 1189–1197 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Forbes, J. M. & Cooper, M. E. Mechanisms of diabetic complications. Physiol. Rev. 93, 137–188 (2013).
  Article CAS PubMed Google Scholar
• Badal, S. S. & Danesh, F. R. New insights into molecular mechanisms of diabetic kidney disease. Am. J. Kidney Dis. 63, S63–S83 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Nishikawa, T. et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404, 787–790 (2000).
  Article CAS PubMed Google Scholar
• Mulder, S. et al. A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes. Diabetes Obes. Metab. 22, 1157–1166 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Shigiyama, F. et al. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc. Diabetol. 16, 84 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Tanaka, A. et al. Effect of empagliflozin on endothelial function in patients with type 2 diabetes and cardiovascular disease: results from the multicenter, randomized, placebo-controlled, double-blind EMBLEM trial. Diabetes Care 42, e159–e161 (2019).
  Article CAS PubMed Google Scholar
• Ishibashi, Y., Matsui, T. & Yamagishi, S. Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm. Metab. Res. 48, 191–195 (2016).
  CAS PubMed Google Scholar
• Salim, H. M. et al. Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse. Front. Cardiovasc. Med. 3, 43 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Juni, R. R. Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by empagliflozin. JACC BasicTransl. Sci. 4, 575–591 (2019).
  Google Scholar
• Sharma, K. Mitochondrial hormesis and diabetic complications. Diabetes 64, 663–672 (2015). Interesting review about the role and source of ROS in the development of DKD and challenging the dogma that ROS are derived from mitochondrial overproduction.
  Article CAS PubMed PubMed Central Google Scholar
• Zhan, M., Brooks, C., Liu, F., Sun, L. & Dong, Z. Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology. Kidney Int. 83, 568–581 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Funk, J. A., Odejinmi, S. & Schnellmann, R. G. SRT1720 induces mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells. J. Pharmacol. Exp. Ther. 333, 593–601 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Scarpulla, R. C. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol. Rev. 88, 611–638 (2008).
  Article CAS PubMed Google Scholar
• Sharma, K. et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J. Am. Soc. Nephrol. 24, 1901–1912 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Rasbach, K. A. & Schnellmann, R. G. PGC-1alpha over-expression promotes recovery from mitochondrial dysfunction and cell injury. Biochem. Biophys. Res. Commun. 355, 734–739 (2007).
  Article CAS PubMed Google Scholar
• Zhao, M. et al. PGC-1alpha overexpression protects against aldosterone-induced podocyte depletion: role of mitochondria. Oncotarget 7, 12150–12162 (2016).
  Article PubMed PubMed Central Google Scholar
• Sharma, K. Obesity and diabetic kidney disease: role of oxidant stress and redox balance. Antioxid. Redox Signal. 25, 208–216 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Sedeek, M. et al. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am. J. Physiol. Renal Physiol. 299, F1348–F1358 (2010).
  Article CAS PubMed Google Scholar
• Gorin, Y. et al. Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes. Am. J. Physiol. Renal Physiol. 308, F1276–F1287 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Gray, S. P. et al. Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease. Diabetologia 60, 927–937 (2017).
  Article CAS PubMed Google Scholar
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02010242 (2015).
• Takagi, S. et al. Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. J. Diabetes Investig. 9, 1025–1032 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Ishibashi, Y., Matsui, T., Yamagishi, S. & Tofogliflozin, A. Highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm. Metab. Res. 48, 191–195 (2016).
  CAS PubMed Google Scholar
• Fioretto, P., Zambon, A., Rassato, M., Busetto, L. & Vettor, R. SGLT inhibitors and the diabetic kidney. Diabetes Care 39, S165–S171 (2016).
  Article CAS PubMed Google Scholar
• Bielesz, B. et al. Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J. Clin. Invest. 120, 4040–4054 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Mariappan, M. M. et al. Combined acute hyperglycemic and hyperinsulinemic clamp induced profibrotic and proinflammatory responses in the kidney. Am. J. Physiol. Cell Physiol. 306, C202–C211 (2014). This study documents that hyperinsulinaemia, as a compensatory response to insulin resistance, activates multiple profibrotic and pro-inflammatory genes in the kidney.
  Article CAS PubMed Google Scholar
• Park, I. S., Kiyomoto, H., Abboud, S. L. & Abboud, H. E. Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes. Diabetes 46, 473–480 (1997).
  Article CAS PubMed Google Scholar
• Meng, X. M., Nikolic-Paterson, D. J. & Lan, H. Y. TGF-β: the master regulator of fibrosis. Nat. Rev. Nephrol. 12, 325–338 (2016). Excellent review on the role of TGFβ in chronic kidney disease.
  Article CAS PubMed Google Scholar
• Hunt, K. J. et al. Levels of connective tissue growth factor (CTGF) predict development of kidney dysfunction in type 2 diabetes — the VADT study. Diabetes https://doi.org/10.2337/db18-528-P (2018).
  Article PubMed Google Scholar
• Rysz, J. et al. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy. J. Nephrol. 20, 444–452 (2007).
  CAS PubMed Google Scholar
• Vallon, V. The proximal tubule in the pathophysiology of the diabetic kidney. Am. J. Physiol. Regul. Integr. Comp. Physiol. 300, R1009–R1022 (2011).
  Article CAS PubMed Google Scholar
• Koszegi, S. et al. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition. J. Physiol. 597, 193–209 (2019).
  Article CAS PubMed Google Scholar
• Panchapakesan, U. et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells–renoprotection in diabetic nephropathy? PLoS One 8, e54442 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Li, C. et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc. Diabetol. 18, 15 (2019).
  Article PubMed PubMed Central Google Scholar
• Kang, S. et al. Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results. Can. J. Cardiol. 36, 543–553 (2020).
  Article PubMed Google Scholar
• Packer, M. Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation 136, 1548–1559 (2017). Comprehensive overview of the role of the NHE in the development of myocardial fibrosis, oxidative stress, inflammation and cardiac remodelling.
  Article CAS PubMed Google Scholar
• Wilcox, C. S. Antihypertensive and renal mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) inhibitors. Hypertension 75, 894–901 (2020).
  Article CAS PubMed Google Scholar
• Klisic, J., Nief, V., Reyes, L. & Ambuhl, P. M. Acute and chronic regulation of the renal Na/H+ exchanger NHE3 in rats with STZ-induced diabetes mellitus. Nephron Physiol. 102, 27–35 (2006).
  Article CAS Google Scholar
• Beloto-Silva, O., Machado, U. F. & Oliveira-Souza, M. Glucose-induced regulation of NHEs activity and SGLTs expression involves the PKA signaling pathway. J. Membr. Biol. 239, 157–165 (2011).
  Article CAS PubMed Google Scholar
• Ganz, M. B., Hawkins, K. & Reilly, R. F. High glucose induces the activity and expression of Na(+)/H(+) exchange in glomerular mesangial cells. Am. J. Physiol. Renal Physiol. 278, F91–F96 (2000).
  Article CAS PubMed Google Scholar
• Thomson, S. C. & Vallon, V. Renal effects of sodium-glucose co-transporter inhibitors. Am. J. Med. 132, S30–S38 (2019). The review emphasizes the link between SGLT2 inhibitors and NHE in the development of DKD.
  Article CAS Google Scholar
• Coady, M. J. et al. MAP17 is a necessary activator of renal Na+/Glucose cotransporter SGLT2. J. Am. Soc. Nephrol. 28, 85–93 (2017). This article demonstrates that MAP links SGLT and NHE, providing a mechanism via which SGLT2 inhibitors can block the sodium–hydrogen exchanger.
  Article CAS PubMed Google Scholar
• Inoue, B. H. et al. Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302, R166–R174 (2012).
  Article CAS PubMed Google Scholar
• Baartscheer, A. et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia 60, 568–573 (2017).
  Article CAS PubMed Google Scholar
• von Lewinski, D. et al. Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients. Metabolism 59, 1020–1028 (2010).
  Article CAS Google Scholar
• Pessoa, T. D., Campos, L. C., Carraro-Lacroix, L., Girardi, A. C. & Malnic, G. Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. J. Am. Soc. Nephrol. 25, 2028–2039 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Onishi, A. et al. Effect of renal tubule-specific knockdown of the Na+/H+ exchanger NHE3 in Akita diabetic mice. Am. J. Physiol. Renal Physiol. 317, F419–F434 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Cuervo, A. M. et al. Autophagy and aging: the importance of maintaining “clean” cells. Autophagy 1, 131–140 (2005).
  Article PubMed Google Scholar
• Jheng, H. F. et al. Mitochondrial fission contributes to mitochondrial dysfunction and insulin resistance in skeletal muscle. Mol. Cell Biol. 32, 309–319 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Huber, T. B. et al. Emerging role of autophagy in kidney function, diseases and aging. Autophagy 8, 1009–1031 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Higgins, G. C. & Coughlan, M. T. Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy? Br. J. Pharmacol. 171, 1917–1942 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Lin, T.-A., Wu, V. C.-C. & Wang, C.-Y. Autophagy in chronic kidney disease. Cells 8, 61 (2019). Up-to-date review on the role of autophagy in the development of chronic kidney disease.
  Article CAS PubMed Central Google Scholar
• Ding, Y. & Choi, M. E. Autophagy in diabetic nephropathy. J. Endocrinol. 224, R15–R30 (2015).
  Article CAS PubMed Google Scholar
• Xin, W. et al. Autophagy protects human podocytes from high glucose-induced injury by preventing insulin resistance. Metabolism 65, 1307–1315 (2016).
  Article CAS PubMed Google Scholar
• Kitada, M. et al. Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of Sirt1 in diabetic Wistar fatty (fa/fa) rats: a model of type 2 diabetes. Exp. Diabetes Res. 2011, 908185 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• Lee, S.-Y. et al. PGC1 α activators mitigate diabetic tubulopathy by improving mitochondrial dynamics and quality control. J. Diabetes Res. 2017, 6483572 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Yu, L. et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature 465, 942–946 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, Y. H. et al. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. Am. J. Physiol. Renal Physiol. 317, F767–F780 (2019).
  Article CAS PubMed Google Scholar
• Hawley S. A. et al. Diabetes 65, 2784–2794 (2016).
• Daniele, G. et al. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care 39, 2036–2041 (2016). This article demonstrates that SGLT2 inhibitors create a state of energy depletion, which can secondarily improve autophagy and mitochondrial dysfunction in patients with type 2 diabetes.
  Article CAS PubMed PubMed Central Google Scholar
• Ferrannini, E. et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65, 1190–1195 (2016).
  Article CAS PubMed Google Scholar